期刊文献+

噻唑蓝法检测中药复方对人白血病CD34^+CD38^-干细胞群的影响 被引量:3

MTT study on the response of human CD34^+/CD38^- leukemic stem cell to traditional Chinese recipes
下载PDF
导出
摘要 目的运用噻唑蓝(MTT)法检测中药益气养阴方及其拆方后的扶正组方、祛邪组方对人白血病CD34+CD38-干细胞群的影响。方法免疫磁珠分离人白血病CD34+CD38-干细胞群,MTT法检测中药复方对细胞生长的影响。结果益气养阴制剂对白血病干细胞的体外抑制率为(24.390±0.046)%,扶正组抑制率为(9.270±0.052)%,祛邪组为(9.370±0.017)%,益气养阴组与扶正组、祛邪组比较差异均有统计学意义(P<0.05),扶正组与祛邪阻比较差异无统计学意义。结论益气养阴方对白血病干细胞有明显抑制作用。 Objective To determine the response of human CD34^+/CD38^- leukemic stem cell (LSCs) to Yiqi Yangyin Fang, a traditional Chinese formula, used as a full package or part of its supportive or aggressive components. Methods Magnetic activated cell sorting (MACS) was used to select CD34^+/CD38^- LSCs. The growth of these cells in response to TCM recipes was determined with MTF assay. Results The growth inhibition was found in (24.390±0.046)% of LSCs exposed to full-package Yiqi Yangyin Fang, compared with (9.270±0.052)% of those exposed to the supportive components and (9.370±0.017)% exposed to aggressive components. CD34^+/CD38^- LSCs were more susceptible to the full-package than to either of its components (P〈0.05) which did not show difference between each other. Conclusion The Yiqi Yangyin formula exhibited remarkable inhibitory effects on leukemic stem cells.
出处 《中国药物与临床》 CAS 2008年第9期696-698,共3页 Chinese Remedies & Clinics
基金 国家自然科学基金资助项目(30672746)
关键词 白血病 噻唑蓝 免疫磁珠 Leukemia MTF assay MACS
  • 相关文献

参考文献7

  • 1Lapidot T, Sirard C, Vormoor J, et al. A cell initiating human acute myeloid leukemia after transplantation into SCID mice.Nature ,1994,367:645-648.
  • 2Blair A, Hogge DE, Ailles LE, et al. Lack of expression of Thy-1 (CD 90)on acute myeloid leukemia cells with long-term proliferative ability in vitro and in vivo. Blood,1997,89:3104-3112.
  • 3Jordan CT, Upchurch D, Szilvassy SJ, et al. The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem eells.Leukemia,2000,14:1777-1784.
  • 4Brendel C, Neubauer A. Characteristics and analysis of normal and leukemic stem cells: current concepts and future directions. Leukemia, 2000,14(10):1711-1717.
  • 5Blair A, Hogge DE, Sutherland HJ. Most acute myeloid leukemia progenitor cells with long-term proliferative ability in vitro and in vivo have the phenotype CD34 (+)/CD71 (-)/HLA-DR. Blood, 1998,92( 11 ) :4325-4335.
  • 6Burton JD. The MTT assay to evaluate chemosensitivity. Methods Mol Med, 2005, 110(1): 69-78.
  • 7肖艳,李俊东,史泓浏,刘继红,冯艳玲,李孟达.MTT法体外药敏实验预测宫颈癌细胞药物敏感性的初步探讨[J].癌症,2007,26(4):386-389. 被引量:17

二级参考文献10

  • 1Burton J D.The MTT assay to evaluate chemosensitivity[J ].Methods Mol Med,2005,110(1):69-78.
  • 2Scheithauer W,Clark G M,Salmon S E,et al.Model for estimation of clinically achievable plasma concentrations for investigational anticancer drugs in man[J].Cancer Treat Rep,1986,70(12):1379-1382.
  • 3Parkin D M,Bray F,Ferlay J,et al.Global cancer statistics,2002[J].CA Cancer J Clin,2005,55(2):74-108.
  • 4Moore D H.Treatment of stage IB2 (bulky) cervical carcinoma[J].Cancer Treat Rev,2003,29(5):401-406.
  • 5Sultana H,Kigawa J,Kanamori Y,et al.Chemosensitivity and p53-Bax pathway-mediated apoptosis in patients with uterine cervical cancer[J].Ann Oncol,2003,14(2):214-219.
  • 6Sargent J M.The use of the MTT assay to study drug resistance in fresh tumour samples[J].Recent Results Cancer Res,2003,161 (1):13-25.
  • 7Taylor C G,Sargent J M,Elgie A W,et al.Chemosensitivity testing predicts survival in ovarian cancer[J].Eur J Gynaecol Oncol,2001,22(4):278-282.
  • 8Tinker A V,Bhagat K,Swenerton K D,et al.Carboplatin and paclitaxel for advanced and recurrent cervical carcinoma:the British Columbia Cancer Agency experience[J].Gynecol Oncol,2005,98(1):54-58.
  • 9Rose P G,Blessing J A,Gershenson D M,et al.Paclitaxel and cisplatin as first-line therapy in recurrent or advanced squamous cell carcinoma of the cervix:a gynecologic oncology group study[J].J Clin Oncol,1999,17(9):2676-2680.
  • 10Duenas-Gonzalez A,Lopez-Graniel C,Gonzalez-Enciso A,et al.A phase Ⅱ study of multimodality treatment for locally advanced cervical cancer:neoadjuvant carboplatin and paclitaxel followed by radical hysterectomy and adjuvant cisplatin chemoradiation[J].Ann Oncol,2003,14(8):1278-1284.

共引文献16

同被引文献34

  • 1赵谢兰,雷瑚仪,高欣,陈方平.急性髓性白血病骨髓细胞NF-κB活性及其与WT1和Bcl-2表达的关系[J].中国医师杂志,2006,8(7):880-882. 被引量:5
  • 2赵嘉惠,张华屏,王春芳.MTT法在检测细胞增殖方面的探讨[J].山西医科大学学报,2007,38(3):262-263. 被引量:92
  • 3Guzman ML,Swiderski CF,Howard DS,et al.Preferential induction of apoptosis for primary human leukemic stem cells.Proc Natl Acad Sci USA,2002,99(25):16220-16225.
  • 4Burton JD.The MTT assay to evaluate chemosensitivity.Methods Mol Med.2005;110(1):69-78.
  • 5Guzman ML,Jordan CT.Considerations for Targeting Malignant Stem Cells in Leukemia.Cancer control.2004;11(2):97-104.
  • 6Yuan H,Li X,Wu J,et al.Strategies to overcome or circumvent P-glycoprotein mediated multidrug resistance.Curr Med Chem.2008;15(5):470-476.
  • 7Sun B,Karin M.NF-kappaB signaling,liver disease and hepatoprotective agents.Oncogene.2008;27 (48):6228-6244.
  • 8Guzman ML,Swiderski CF,Howard DS,et al.Preferential induction of apoptosis for primary human leukemic stem cells.Proc Natl Acad Sci USA.2002;99 (25):16220-16225.
  • 9Chan WI,Huntl Y.Leukemia stem cells in acute myeloid leukemia.Semin Oncol.2008; 35(4):326-335.
  • 10Hosen N,Park CY,TatsumiN,et al.CD96 is a leukemic stem cell-specificmarker in human acutemyeloid leukemia.Proc Natl Acad SciUSA.2007;104(26):11008-11013.

引证文献3

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部